Trial · NCT05391893
Effect of Oral and Intravenous Diltiazem Protocol for Emergency Department Atrial Fibrillation
NCT05391893, Phase 4, Completed, Corewell Health South; results first posted 2024-12-27
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. Effect of Oral and Intravenous Diltiazem Protocol for Emergency Department Atrial Fibrillation. Trials, record NCT05391893. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT05391893
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Effect of Oral and Intravenous Diltiazem Protocol for Emergency Department Atrial Fibrillation
- NCT number
- NCT05391893
- Status
- Completed
- Phases
- Phase 4
- Enrollment
- 444 participants, actual
- Lead sponsor
- Corewell Health South
- Conditions
- Atrial Fibrillation, Atrial Flutter
- Interventions
- Oral, Intravenous drug
- First posted
- 2022-05-26
- Last updated
- 2024-12-27
- Results first posted
- 2024-12-27
Source ClinicalTrials.gov
Registered outcomes3
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Admission Rate | 1 days | This will compare rates of patients admitted between the protocol group and patients treated traditionally |
| Primary | Treatment Success at 3 Hours | 3 hours | This will compare the total number of patients who in 3 hours from first medicine administration achieved heart rate less than 110 between the protocol and traditional treatment group |
| Secondary | Rate of Hypotension | 1 day | rates of patients experiencing systolic blood pressure less than 90 |
Source ClinicalTrials.gov
Outcomes3
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
| Type | Outcome | Time frame | Population | Units | Measured as |
|---|---|---|---|---|---|
| PRIMARY | Admission Rate | 1 days | Participants | COUNT_OF_PARTICIPANTS | |
| PRIMARY | Treatment Success at 3 Hours | 3 hours | Participants | COUNT_OF_PARTICIPANTS | |
| SECONDARY | Rate of Hypotension | 1 day | Participants | COUNT_OF_PARTICIPANTS |
Source ClinicalTrials.gov
Results by group6
Each measurement the trial posted, group by group, in the words and numbers it posted.
| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Admission Rate | Diltiazem With Oral and Intravenous Treatment | 98 | Participants | ||
| Admission Rate | Traditional Atrial Fibrillation With Rapid Ventricular Response | 188 | Participants | ||
| Treatment Success at 3 Hours | Diltiazem With Oral and Intravenous Treatment | 150 | Participants | ||
| Treatment Success at 3 Hours | Traditional Atrial Fibrillation With Rapid Ventricular Response | 192 | Participants | ||
| Rate of Hypotension | Diltiazem With Oral and Intravenous Treatment | 7 | Participants | ||
| Rate of Hypotension | Traditional Atrial Fibrillation With Rapid Ventricular Response | 17 | Participants |
Source ClinicalTrials.gov
Participant flow6
How many started, completed or left each group, period by period.
| Period | Milestone | Group | Participants | Units counted |
|---|---|---|---|---|
| Overall Study | STARTED | Diltiazem With Oral and Intravenous Treatment | 177 | |
| Overall Study | STARTED | Traditional Atrial Fibrillation With Rapid Ventricular Response | 267 | |
| Overall Study | COMPLETED | Diltiazem With Oral and Intravenous Treatment | 172 | |
| Overall Study | COMPLETED | Traditional Atrial Fibrillation With Rapid Ventricular Response | 249 | |
| Overall Study | NOT COMPLETED | Diltiazem With Oral and Intravenous Treatment | 5 | |
| Overall Study | NOT COMPLETED | Traditional Atrial Fibrillation With Rapid Ventricular Response | 18 |
Source ClinicalTrials.gov
Adverse events2
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
| Type | Event | Organ system | Group | Affected | At risk | Events |
|---|---|---|---|---|---|---|
| other | Hypotension | Vascular disorders | Diltiazem With Oral and Intravenous Treatment | 7 | 177 | |
| other | Hypotension | Vascular disorders | Traditional Atrial Fibrillation With Rapid Ventricular Response | 17 | 267 |
Source ClinicalTrials.gov
Adverse event totals6
The totals the trial posted for each group.
| Total | Group | Affected | At risk |
|---|---|---|---|
| Total, all-cause mortality | Diltiazem With Oral and Intravenous Treatment | 0 | 177 |
| Total, all-cause mortality | Traditional Atrial Fibrillation With Rapid Ventricular Response | 1 | 267 |
| Total, other adverse events | Diltiazem With Oral and Intravenous Treatment | 7 | 177 |
| Total, other adverse events | Traditional Atrial Fibrillation With Rapid Ventricular Response | 17 | 267 |
| Total, serious adverse events | Diltiazem With Oral and Intravenous Treatment | 0 | 177 |
| Total, serious adverse events | Traditional Atrial Fibrillation With Rapid Ventricular Response | 0 | 267 |
Source ClinicalTrials.gov
Papers0
The papers the trial lists on ClinicalTrials.gov.
None in this release.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons5
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
| Comparison | Source |
|---|---|
| Diltiazem With Oral and Intravenous Treatment vs Traditional Atrial Fibrillation With Rapid Ventricular Response: Rate of Hypotension | Trial comparisons |
| Diltiazem With Oral and Intravenous Treatment vs Traditional Atrial Fibrillation With Rapid Ventricular Response: Admission Rate | Trial comparisons |
| Diltiazem With Oral and Intravenous Treatment vs Traditional Atrial Fibrillation With Rapid Ventricular Response: Treatment Success at 3 Hours | Trial comparisons |
| Diltiazem With Oral and Intravenous Treatment vs Traditional Atrial Fibrillation With Rapid Ventricular Response: deaths from any cause | Trial comparisons |
| Diltiazem With Oral and Intravenous Treatment vs Traditional Atrial Fibrillation With Rapid Ventricular Response: serious adverse events | Trial comparisons |
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT05391893
GET https://conductscience.org/api/trials/v1/NCT05391893/registered